Vimseltinib

Vimseltinib, sold under the brand name Romvimza, is an anti-cancer medication used for the treatment of tenosynovial giant cell tumor. Vimseltinib is a kinase inhibitor. Vimseltinib is a macrophage colony-stimulating factor receptor antagonist. The most common adverse reactions, including laboratory abnormalities, include increased aspartate aminotransferase, periorbital edema, fatigue, rash, increased cholesterol, peripheral edema, face edema, decreased neutrophils, decreased leukocytes, pruritus, and increased alanine aminotransferase. Vimseltinib was approved for medical use in the United States in February 2025.
Wikipedia contributors, "Vimseltinib", Wikipedia, revision 1383061118, retrieved 20 November 2026, source, CC BY-SA 4.0.